The U.S. Food and Drug Administration has granted Fast Track designation to SRF388 for the treatment of patients with hepatocellular carcinoma (HCC), according to a press release.
“Liver cancer is the most rapidly increasing type of cancer in both men and women in the US, with incidences tripling since 1980. There is a significant need to expedite the development of new therapies to treat liver cancer as the five-year survival for patients with unresectable or metastatic liver cancer is less than five percent,” said Rob Ross, MD, chief medical officer, in a company press release. “SRF388 targets IL-27, an immunosuppressive cytokine that has been found to be elevated in patients with liver cancer, as well as kidney cancer, and we believe SRF388 has the potential to be an effective treatment option for these patients, as monotherapy or in combination with anti-PD-1 therapies.”
Read the full press release here.